By Daniel Sabet · Cannabis CFO & Financial Advisor, GreenGrowth CPAs · 280E, Capital Markets & Growth Planning · Los Angeles, CA | Published August 3, 2026 | Cannabis Advisory
Cannabis uplisting stopped being theoretical in June 2026. Trulieve began trading on the New York Stock Exchange on June 10, the first US plant-touching operator ever to reach a major domestic exchange. Glass House Brands secured NYSE approval weeks later. Almost every article written since has covered the legal side of how that became possible. Very few have covered what actually stood between those companies and the opening bell. That was an accounting problem. Exchange policy bars a listed company from consolidating adult-use marijuana operations. So a dual-license operator has to deconsolidate them, then produce audited carve-out financial statements for whatever remains.
QUICK ANSWER
Cannabis uplisting is the move from the Canadian Securities Exchange or the OTC markets onto the NYSE or Nasdaq. It became possible for US operators after the April 2026 order placed state-licensed medical marijuana in Schedule III. Adult-use marijuana remains in Schedule I, and exchanges will not list a company that consolidates federally prohibited operations. So a dual-license operator deconsolidates its adult-use business, proves loss of control under US GAAP, rebuilds historical results as standalone carve-out statements, then has a PCAOB-registered firm audit them. GreenGrowth CPAs is PCAOB registered and has served cannabis operators since 2016.
Cannabis Uplisting: At a Glance
What Every Operator Considering a Listing Needs to Know
- Two-tier federal framework: State-licensed medical marijuana sits in Schedule III. Adult-use, unlicensed marijuana and synthetic THC remain in Schedule I.
- Deconsolidation is the gate: Exchange policy blocks a listed company from consolidating non-medical marijuana operations. Trulieve restructured to separate its dual-market operations before listing.
- Auditors test loss of control, they do not assume it: Retained board seats, management agreements, supply agreements and call options can all keep control with the parent even after a nominal separation.
- Carve-out statements are demanding: Shared costs must be allocated on a reasonable and consistently applied basis, and historical periods rebuilt at entity level even if the entity did not legally exist then.
- PCAOB audit is not an upgraded private audit: Different standards, documentation and independence rules, with workpapers subject to PCAOB inspection. Prior years audited under private company standards generally need reaudit.
- Section 280E relief is a separate question: Tax relief follows the substance sold. Listing eligibility follows the consolidated reporting entity. An operator can have one without the other.
- GreenGrowth’s role: We assess listing readiness, support carve-out structuring alongside securities counsel, and perform PCAOB-standard audits. Book an uplisting readiness review →
Why Trulieve Reached the NYSE First
Trulieve was not simply the largest or most profitable candidate. It was the operator that could most cleanly restructure around the narrow category the April 2026 order actually rescheduled. The order moved state-licensed medical marijuana and FDA-approved marijuana products into Schedule III and left everything else in place. Because current exchange policy bars a listed company from consolidating businesses that remain federally prohibited, Trulieve deconsolidated operations in markets where it served both medical and adult-use customers and presented the exchange with an entity whose consolidated results reflected Schedule III activity.
In practice, that is now the cannabis uplisting template. Every operator studying one asks the same question: can we reorganize the corporate structure so the listed entity consolidates only rescheduled activity, and can we produce audited financial statements that support it. For the underlying tax mechanics that sit alongside this, see our cannabis accounting services page.
💬 The Conversation Worth Having
Almost every operator we work with runs a consolidated ledger. Nobody tracks anything at the entity level, because until now nobody needed to. The moment you have to show what a single license produced in isolation for two prior years, that gap stops being a bookkeeping preference and becomes your entire timeline. The operators who move fastest through a listing are not the biggest ones. They are the ones whose historical records survive reconstruction without guesswork.
Could your historical records support entity-level financial statements for two prior years? We can tell you in one review.
Cannabis Uplisting Starts With Deconsolidation
Deconsolidation, the first real hurdle in any cannabis uplisting, means the removal of a subsidiary or business from a parent’s consolidated financial statements. It is not a paper exercise and it is not reversible on a whim. The parent must genuinely give up control as US GAAP defines that term, and an auditor tests that conclusion rather than accepting it.
The Five Questions an Auditor Will Work Through
Has control actually transferred? Deconsolidation requires loss of a controlling financial interest. Retained voting rights, board seats, management agreements and call options all matter here. Any one of them can leave control with the parent after a separation that looks complete on paper.
Is there a variable interest? If the adult-use entity runs thin on capital and depends economically on the parent, the variable interest entity guidance may pull it back into consolidation regardless of legal ownership.
How is the retained interest measured? A parent keeping a non-controlling stake measures it at fair value on the deconsolidation date, then recognizes a gain or loss. For a cannabis business with no clean market comparables, that valuation is a significant estimate. Auditors scrutinize it closely.
What continues between the parties? Shared real estate, licenses, staff, intercompany supply and management fees all survive the separation. Each one requires related party disclosure.
Do the state regulators agree? Cannabis licenses are not freely transferable either. A restructuring that satisfies US GAAP but breaches state licensing rules solves nothing. In our experience, this is the constraint that most often forces a redesign late in the process.
What Carve-Out Financial Statements Require
Once operations are separated, a cannabis uplisting candidate needs financial statements presenting it as a standalone business for the historical periods, not only going forward. Those are carve-out financial statements, and they sit among the more demanding engagements in financial reporting.
Allocating Shared Costs
A multi-state operator approaching a cannabis uplisting runs one accounting department, one compliance function and one insurance program. Often it runs one lease across both medical and adult-use activity. Carve-out statements require you to allocate those shared costs on a reasonable and consistent basis, and to disclose the method. Headcount, square footage, revenue and direct labor hours are each defensible in different circumstances. Picking one and applying it inconsistently across periods is not.
Reconstructing the Historical Periods
The entity you present may never have existed as a separate legal entity during the reporting periods. The financial statements still have to show it as though it did. That means rebuilding revenue, cost of goods sold, inventory and payroll at a granularity most cannabis operators have never maintained. Here, seed-to-sale tracking and point-of-sale detail stop being a compliance chore. They become the evidentiary basis for a securities filing.
Documenting the Basis of Presentation
Carve-out statements carry an explicit note describing what you included, what you excluded, how you determined allocations and why the presentation is meaningful. SEC staff read that note closely during review. As a result, a vague one invites comment letters that add months to a timeline.
PCAOB Audits and the Two-Year Rule
Any company filing a registration statement with the Securities and Exchange Commission must engage a firm registered with the Public Company Accounting Oversight Board, applying PCAOB standards. A company entering the public markets generally presents at least two years of statements audited on that basis. The precise requirement turns on filer status and the form used. The SEC sets out how these requirements apply across filing types in its Financial Reporting Manual.
What Cannabis Uplisting Changes About Your Audit
A PCAOB audit is not an upgraded private company audit. The standards, documentation requirements, independence rules and inspection regime all differ, and the PCAOB inspects the workpapers themselves.
Independence restrictions are stricter. A firm providing bookkeeping, valuation or outsourced CFO services generally cannot audit the same issuer. So operators who use one advisor for everything usually split the relationship well ahead of a filing.
Prior-year statements may need reaudit. Historical financials that carry a private company audit opinion, or an opinion from a firm outside the PCAOB register, generally cannot go into the filing as they stand. Consequently, this is the single item that most often moves a timeline from weeks to quarters.
▶ Where Cannabis Operators Typically Fail Exchange Listing Standards
| Requirement | What It Tests | Why Operators Struggle |
|---|---|---|
| Minimum bid price | Share price floor at listing and ongoing | Years of drawdowns; reverse splits precede applications |
| Public float value | Market value of unrestricted publicly held shares | Concentrated insider ownership shrinks qualifying float |
| Equity or income standard | Stockholders’ equity, or earnings history | 280E has suppressed reported net income for years |
| Audited financials | PCAOB-audited statements for required periods | Many operators have never had a PCAOB-standard audit |
| Qualitative review | Exchange discretion on suitability | Any remaining Schedule I activity in the group |
Confirm current thresholds directly with the exchange. Listing guides are revised regularly and neither exchange has published cannabis-specific criteria.
Cannabis Uplisting Signals to Watch
The clearest public indicator that an operator is preparing a cannabis uplisting is a reverse stock split announced in those terms. In mid-2026 Curaleaf announced a one-for-three reverse split and Verano a one-for-five. Both framed the move as preparation for a US exchange listing. A reverse split lifts the share price toward exchange minimums without changing the underlying business. For that reason it tends to arrive before an application rather than after.
Observers have consistently cautioned that Trulieve’s position was unusual. Scale and profitability alone are not enough. Operators with a significant adult-use presence face the harder version. The deconsolidation is larger, and the business that remains is smaller.
Separately, the DEA’s expedited administrative hearing on broader rescheduling opened on June 29, 2026 and concluded on July 15 after seventeen days of testimony. Chief Administrative Law Judge Derek Julius gave participants until August 17, 2026 to file post-hearing briefs of up to fifty pages. He then writes a recommendation. The final decision rests with the DEA Administrator and no timeline has been announced for either step. A consolidated legal challenge to the April order is separately underway. Filings and status are published on the DEA marijuana rescheduling page. If that proceeding eventually extends Schedule III to adult-use marijuana, the dual-license structuring problem narrows sharply. Until then, an operator planning a listing builds for the framework that exists today.
How GreenGrowth CPAs Supports Cannabis Uplisting
GreenGrowth CPAs has worked with cannabis operators since 2016. The firm holds PCAOB registration and AICPA membership. That combination is uncommon. Most PCAOB-registered firms have limited cannabis experience. Most cannabis accounting firms never registered with the PCAOB. Work relevant to a listing falls into three phases. First, a readiness assessment of structure, licenses and historical records. Second, carve-out structuring support alongside securities counsel while the restructuring is still on the drawing board. Third, the PCAOB-standard audit itself.
Why the Auditor Decision Comes First
Independence rules mean one firm generally cannot both build the carve-out statements and audit them. Deciding which role we should hold is part of an early conversation, not an afterthought. Our cannabis IPO services page covers the audit side in more detail.
KEY TAKEAWAYS
- ›Cannabis uplisting became possible in June 2026 when Trulieve listed on the NYSE, but only for operators that can isolate Schedule III activity in the listed entity.
- ›Deconsolidation requires genuine loss of control under US GAAP. Retained board seats, management agreements and call options can defeat it, and an auditor tests the conclusion rather than accepting it.
- ›Carve-out financial statements require shared costs allocated on a consistent disclosed basis and historical periods rebuilt at entity level, which depends entirely on the quality of seed-to-sale and point-of-sale records.
- ›At least two years of PCAOB-audited statements are generally required. Prior years audited under private company standards usually need reaudit, which is the item that most often extends timelines by quarters.
- ›Section 280E relief and listing eligibility run on separate mechanisms. Tax relief follows the substance sold; listing eligibility follows the consolidated reporting entity.
- ›Independence rules prevent one firm from both preparing carve-out statements and auditing them, so the auditor decision should be made early rather than at filing.
Cannabis Uplisting Questions Answered
What is cannabis uplisting?+
Cannabis uplisting means moving a listed cannabis company’s shares from a smaller venue, such as the Canadian Securities Exchange or the OTC markets, onto the New York Stock Exchange or Nasdaq. It became possible for US plant-touching operators in June 2026, when Trulieve became the first to list on the NYSE.
Why does uplisting require deconsolidation of adult-use operations?+
The April 2026 rescheduling order moved only state-licensed medical marijuana and FDA-approved marijuana products to Schedule III. Adult-use marijuana remains in Schedule I. Exchange policy does not permit a listed company to consolidate businesses involved in non-medical marijuana, so an operator serving both markets must remove those operations from its consolidated financial statements before listing.
How many years of audited financial statements does a cannabis company need to go public?+
A company entering the US public markets generally presents at least two years of financial statements audited under PCAOB standards. The exact requirement depends on filer status and the registration form used. If prior periods were audited under private company standards or by a firm not registered with the PCAOB, those periods usually need to be reaudited before they can be included in a filing.
What are carve-out financial statements?+
Carve-out financial statements present a business as though it operated on a standalone basis during historical periods when it was actually part of a larger group. They require three things: shared costs allocated on a reasonable and consistent basis, historical results reconstructed at entity level, and an explicit note covering what you included, what you excluded and how you determined allocations.
Audit and Auditor Questions
Can our current accountant audit us for an SEC filing?+
Only if that firm is registered with the PCAOB and satisfies the applicable independence requirements. A firm providing bookkeeping, valuation or outsourced CFO services generally cannot serve as that company’s PCAOB auditor. So many operators separate those relationships well before a filing.
Does Section 280E relief mean our company can uplist?+
No. Section 280E relief and exchange listing eligibility are governed by two separate mechanisms. Section 280E relief follows the substance being sold, so a state-licensed medical operator obtained relief from the April 2026 order directly. Exchange eligibility follows the consolidated reporting entity. So a company can hold medical licenses and still fail if its group includes adult-use operations.
Has adult-use cannabis been rescheduled to Schedule III?+
No. As of August 2026 only state-licensed medical marijuana and FDA-approved marijuana products sit in Schedule III. The DEA’s administrative hearing on broader rescheduling concluded on July 15, 2026, with post-hearing briefs due August 17, 2026. The Chief Administrative Law Judge will then issue a recommendation, and the final decision rests with the DEA Administrator. No timeline has been announced.
Timing and Next Steps
How long does cannabis uplisting preparation take?+
Timelines vary with the condition of the operator’s records and the complexity of the restructuring. One factor extends the schedule more than any other: discovering that prior-year statements require reaudit under PCAOB standards. Operators whose historical records support entity-level reconstruction move considerably faster than those rebuilding from consolidated ledgers.
How does GreenGrowth CPAs help with cannabis uplisting readiness?+
GreenGrowth CPAs is a PCAOB-registered, AICPA member firm that has served cannabis operators since 2016. We assess listing readiness against your structure, licenses and records. We support carve-out structuring alongside securities counsel, and perform PCAOB-standard audits subject to independence rules. To discuss what a listing would take for your operation, book an uplisting readiness review.
The Listing Window Opened. Whether You Can Walk Through It Is an Accounting Question.
Book an uplisting readiness review. We assess your structure, records and audit history against what an S-1 requires, then tell you honestly what the timeline looks like.
Book Your Free Readiness Review →
GreenGrowth CPAs · Cannabis Advisory Team
